EA201490037A1 - Антагонисты trpv4 - Google Patents

Антагонисты trpv4

Info

Publication number
EA201490037A1
EA201490037A1 EA201490037A EA201490037A EA201490037A1 EA 201490037 A1 EA201490037 A1 EA 201490037A1 EA 201490037 A EA201490037 A EA 201490037A EA 201490037 A EA201490037 A EA 201490037A EA 201490037 A1 EA201490037 A1 EA 201490037A1
Authority
EA
Eurasian Patent Office
Prior art keywords
trpv4
antagonists
spirocarbamate
analogs
pharmaceutical compositions
Prior art date
Application number
EA201490037A
Other languages
English (en)
Other versions
EA023616B1 (ru
Inventor
Карл Брукс
Муи Чеунг
Хилари Шенк Эйдам
Криста Б. Гудман
Марлис Хэммонд
Марк А. Хилфикер
Трам Х. Хоанг
Жаклин Р. Паттерсон
Патрик Стой
Госэнь Е
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Publication of EA201490037A1 publication Critical patent/EA201490037A1/ru
Publication of EA023616B1 publication Critical patent/EA023616B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Abstract

Настоящее изобретение относится к аналогам спирокарбамата, содержащим их фармацевтическим композициям и к их применению в качестве антагонистов TRPV4.
EA201490037A 2011-06-17 2012-06-15 Антагонисты trpv4 EA023616B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17
PCT/US2012/042622 WO2013012500A1 (en) 2011-06-17 2012-06-15 Trpv4 antagonists

Publications (2)

Publication Number Publication Date
EA201490037A1 true EA201490037A1 (ru) 2015-12-30
EA023616B1 EA023616B1 (ru) 2016-06-30

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490037A EA023616B1 (ru) 2011-06-17 2012-06-15 Антагонисты trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (ru)
EP (2) EP2721016B1 (ru)
JP (1) JP5969017B2 (ru)
KR (1) KR101870003B1 (ru)
CN (1) CN103732583B (ru)
AR (1) AR086958A1 (ru)
AU (1) AU2012284540B2 (ru)
BR (1) BR112013032391B1 (ru)
CA (1) CA2839743C (ru)
CL (1) CL2013003602A1 (ru)
CO (1) CO6821953A2 (ru)
CR (1) CR20130671A (ru)
CY (1) CY1117792T1 (ru)
DK (1) DK2721016T3 (ru)
DO (1) DOP2013000307A (ru)
EA (1) EA023616B1 (ru)
ES (2) ES2569193T3 (ru)
HK (1) HK1195068A1 (ru)
HR (1) HRP20160539T1 (ru)
HU (1) HUE029594T2 (ru)
IL (1) IL229872A (ru)
JO (1) JO3154B1 (ru)
MA (1) MA35184B1 (ru)
ME (1) ME02416B (ru)
MX (1) MX337440B (ru)
MY (1) MY173521A (ru)
PE (1) PE20141943A1 (ru)
PL (1) PL2721016T3 (ru)
PT (1) PT2721016E (ru)
RS (1) RS54858B1 (ru)
SG (1) SG195106A1 (ru)
SI (1) SI2721016T1 (ru)
SM (1) SMT201600150B (ru)
TW (1) TWI538912B (ru)
UA (1) UA113963C2 (ru)
UY (1) UY34138A (ru)
WO (1) WO2013012500A1 (ru)
ZA (1) ZA201308816B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927585B2 (en) 2011-06-17 2015-01-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
US9487507B2 (en) 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
JPWO2015046193A1 (ja) 2013-09-25 2017-03-09 塩野義製薬株式会社 Trpv4阻害活性を有する芳香族複素環式アミン誘導体
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
ES2813108T3 (es) * 2016-05-19 2021-03-22 Glaxosmithkline Ip No 2 Ltd Antagonista de TRPV4
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
SG11202003825TA (en) * 2017-11-01 2020-05-28 Bristol Myers Squibb Co Spirocyclic compounds as farnesoid x receptor modulators
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
MX2022013607A (es) 2020-04-30 2022-11-16 Raqualia Pharma Inc Derivados de la pirimidina-4(3h)-ona como antagonistas de trpv4.
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
MX2023000610A (es) 2020-07-16 2023-02-13 Raqualia Pharma Inc Inhibidor de trpv4 como agente terapeutico para enfermedades oculares.
WO2024011214A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Therapeutic compounds and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE482945T1 (de) * 1998-05-26 2010-10-15 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
US7566712B2 (en) * 2003-07-16 2009-07-28 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
KR20080070749A (ko) * 2005-11-23 2008-07-30 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
JP2010517967A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド 摂食障害の治療のための1−オキサ−3−アザスピロ[4,5]デカン−2−オン誘導体
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US7998982B2 (en) * 2007-08-09 2011-08-16 Abbott Laboratories Amide derivatives as TRPV1 antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
ES2453075T3 (es) 2008-07-25 2014-04-03 Glaxosmithkline Llc Antagonistas de TRPV4
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd 2−インドールアクリルアミド類縁体
WO2012024183A1 (en) 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
US8927585B2 (en) * 2011-06-17 2015-01-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonists
US9487507B2 (en) * 2011-06-17 2016-11-08 Glaxosmithkline Intellectual Property (No. 2) Limited TRPV4 antagonists

Also Published As

Publication number Publication date
BR112013032391B1 (pt) 2020-11-24
US20140121206A1 (en) 2014-05-01
ES2569193T3 (es) 2016-05-09
CL2013003602A1 (es) 2014-07-04
US9187464B2 (en) 2015-11-17
AR086958A1 (es) 2014-02-05
KR101870003B1 (ko) 2018-06-22
DK2721016T3 (en) 2016-06-06
PL2721016T3 (pl) 2017-01-31
KR20140041733A (ko) 2014-04-04
EP2721016B1 (en) 2016-04-06
EP3121177A1 (en) 2017-01-25
DOP2013000307A (es) 2014-06-01
MY173521A (en) 2020-01-30
CR20130671A (es) 2014-02-04
HRP20160539T1 (hr) 2016-06-17
RS54858B1 (sr) 2016-10-31
EP2721016A1 (en) 2014-04-23
PT2721016E (pt) 2016-06-06
AU2012284540B2 (en) 2014-08-28
EA023616B1 (ru) 2016-06-30
CA2839743A1 (en) 2013-01-24
SG195106A1 (en) 2013-12-30
ZA201308816B (en) 2015-02-25
CO6821953A2 (es) 2013-12-31
CN103732583A (zh) 2014-04-16
MA35184B1 (fr) 2014-06-02
JP2014518214A (ja) 2014-07-28
ME02416B (me) 2016-09-20
TWI538912B (zh) 2016-06-21
BR112013032391A2 (pt) 2016-08-16
SI2721016T1 (sl) 2016-06-30
JO3154B1 (ar) 2017-09-20
CA2839743C (en) 2017-03-28
AU2012284540A1 (en) 2013-04-04
IL229872A (en) 2017-03-30
EP2721016A4 (en) 2014-10-08
WO2013012500A1 (en) 2013-01-24
JP5969017B2 (ja) 2016-08-10
HUE029594T2 (en) 2017-03-28
UA113963C2 (xx) 2017-04-10
CY1117792T1 (el) 2017-05-17
HK1195068A1 (zh) 2014-10-31
UY34138A (es) 2013-01-03
PE20141943A1 (es) 2014-12-28
SMT201600150B (it) 2016-07-01
MX2013014898A (es) 2014-03-21
EP3121177B1 (en) 2018-08-01
NZ618221A (en) 2015-02-27
ES2688733T3 (es) 2018-11-06
TW201313705A (zh) 2013-04-01
MX337440B (es) 2016-03-03
CN103732583B (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
EA201490037A1 (ru) Антагонисты trpv4
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
EA201790781A3 (ru) Противовирусные соединения
EA202190619A1 (ru) Противовирусные соединения
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201790963A1 (ru) Противовирусные соединения
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
EA201590887A1 (ru) Композиция
EA201590534A1 (ru) Новые бициклические производные
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201300388A1 (ru) Соединения замещенного бензамида
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201290772A1 (ru) Новые формы ивабрадина гидрохлорида
EA201500801A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EA201300034A1 (ru) Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG TM